1 Min Read
* GENMAB AND SEATTLE GENETICS TO CO-DEVELOP TISOTUMAB VEDOTIN FOR SOLID TUMORS
* NEWS DOES NOT IMPACT 2017 FINANCIAL GUIDANCE Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.